Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
- PMID: 26599351
- DOI: 10.1002/hep.28368
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Regardless of tumor stage, survival was significantly shorter (P = 0.017) in patients with NAFLD-HCC, 25.5 months (95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P = nonsignificant)
Conclusions: NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment.
© 2015 by the American Association for the Study of Liver Diseases.
Comment in
-
Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study.Hepatobiliary Surg Nutr. 2017 Oct;6(5):350-352. doi: 10.21037/hbsn.2017.06.06. Hepatobiliary Surg Nutr. 2017. PMID: 29152487 Free PMC article. No abstract available.
-
NAFLD-which patients should have hepatocellular carcinoma surveillance?Hepatobiliary Surg Nutr. 2017 Oct;6(5):353-355. doi: 10.21037/hbsn.2017.06.04. Hepatobiliary Surg Nutr. 2017. PMID: 29152488 Free PMC article. No abstract available.
-
Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history.Hepatobiliary Surg Nutr. 2017 Dec;6(6):401-403. doi: 10.21037/hbsn.2017.07.07. Hepatobiliary Surg Nutr. 2017. PMID: 29312975 Free PMC article. No abstract available.
-
Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario.Hepatobiliary Surg Nutr. 2018 Apr;7(2):130-133. doi: 10.21037/hbsn.2018.01.01. Hepatobiliary Surg Nutr. 2018. PMID: 29744343 Free PMC article. No abstract available.
-
Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection.Eur J Gastroenterol Hepatol. 2023 Apr 1;35(4):431-439. doi: 10.1097/MEG.0000000000002504. Epub 2022 Dec 23. Eur J Gastroenterol Hepatol. 2023. PMID: 36728881
Similar articles
-
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.Can J Gastroenterol Hepatol. 2020 Jun 3;2020:4873875. doi: 10.1155/2020/4873875. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 32566546 Free PMC article.
-
Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes.Updates Surg. 2024 Jun;76(3):879-887. doi: 10.1007/s13304-024-01833-3. Epub 2024 Apr 7. Updates Surg. 2024. PMID: 38582796
-
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28. Aliment Pharmacol Ther. 2017. PMID: 28960360
-
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10. Clin J Gastroenterol. 2015. PMID: 25575848 Review.
-
Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):18-27. doi: 10.1016/s1499-3872(11)60120-3. Hepatobiliary Pancreat Dis Int. 2012. PMID: 22251466 Review.
Cited by
-
The perplexity of _targeting genetic alterations in hepatocellular carcinoma.Med Oncol. 2020 Jul 22;37(8):67. doi: 10.1007/s12032-020-01392-8. Med Oncol. 2020. PMID: 32699957 Free PMC article.
-
Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives.Int J Mol Sci. 2024 Jun 25;25(13):6938. doi: 10.3390/ijms25136938. Int J Mol Sci. 2024. PMID: 39000046 Free PMC article. Review.
-
The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.Int J Mol Sci. 2022 Oct 15;23(20):12370. doi: 10.3390/ijms232012370. Int J Mol Sci. 2022. PMID: 36293225 Free PMC article. Review.
-
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome.JHEP Rep. 2024 Apr 24;6(7):101075. doi: 10.1016/j.jhepr.2024.101075. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 38961853 Free PMC article.
-
Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice.Glycoconj J. 2018 Oct;35(5):467-476. doi: 10.1007/s10719-018-9838-3. Epub 2018 Sep 8. Glycoconj J. 2018. PMID: 30194503
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical